This is a working overview of reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-04. Anything still debated is marked as such rather than presented as settled.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Handling practices center on minimizing contamination and adsorption. Lyophilized peptide tends to accumulate static charge, so weighing is done with antistatic measures and calibrated balances. Reconstitution with appropriate solvent should be gentle, avoiding vigorous vortexing that generates foam and shear. Solutions are typically aliquoted before freezing to reduce repeated temperature cycling. Personal protective equipment and a fume hood are standard for powder handling.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
=== Fossilbericht und Evolutionsgeschichte === Seeigel bleiben aufgrund ihres Skeletts aus Kalziumkarbonat häufig als Fossilien erhalten und haben daher einen verhältnismäßig guten Fossilbericht. Am häufigsten gefunden werden isolierte Stacheln oder ganze Gehäuse ohne Stacheln, seltener vollständige Exemplare mit artikulierten Stacheln oder Teile der Laterne. Experimentelle Beobachtungen an heutigen Seeigeln haben gezeigt, dass nach dem Tod des Tieres zunächst die Stacheln und Pedizellarien abfallen, anschließend fällt die Laterne durch die Peristom-Öffnung heraus und zerfällt in Einzelteile. Zuletzt zerbricht das Gehäuse entlang der Plattengrenzen und zerfällt in einzelne Ambulakral- und Interambulakralplatten. Dieser Prozess kann je nach Umweltbedingungen (v. a. Temperatur und Wasserbewegung) wenige Tage bis einige Wochen dauern. Die ältesten Seeigel lassen sich ab dem Mittelordovizium nachweisen (ca. 460 Millionen Jahre vor heute). Frühe Seeigel hatten kugel- bis eiförmige Gehäuse und nur kleine Stacheln, jedoch bereits eine voll funktionale Laterne. Bei allen paläozoischen Seeigeln weicht der Aufbau des Gehäuses von dem moderner Seeigel mit den regelmäßigen Ambulakral- und Interambulakral-Doppelreihen ab: Ambulakralia sind entweder zweireihig oder bestehen aus mehr als zwei Plattenreihen, Interambulakralia haben meistens deutlich mehr als zwei Plattenreihen, die in komplexen regelmäßigen oder unregelmäßigen Mustern angeordnet sein können. Häufig überlappen sich die einzelnen Gehäuseplatten schuppenartig.
Die einzelnen Platten des Gehäuses waren dabei nur über Bindegewebe miteinander verbunden, sodass vollständige Fossilien äußerst selten sind. Wichtige paläozoische Fundstellen mit gut erhaltenen Exemplaren befinden sich beispielsweise in den USA (v. a. Mississippium, aber auch Oberdevon, Pennsylvanium und Perm), in Irland (v. a. Mississippium), Schottland (v. a. Ordovizium und Silur), England (v. a. Silur und Mississippium), Belgien (v. a. Oberdevon und Mississippium) und Deutschland (v. a. Devon). Außerhalb Nordamerikas und Europas sind deutlich weniger Funde bekannt. Bedeutende Familien paläozoischer Seeigel sind beispielsweise die Bothriocidaridae (Mittelordovizium bis Silur), die über ein dickes Gehäuse und große, von Plättchen bedeckte Ambulakralfüßchen verfügten, die Lepidocentridae (Silur bis Pennsylvanium) mit schuppenförmig überlappenden Platten und zweireihigen Ambulakralia, oder die Palaechinidae mit ungewöhnlich dicken, regelmäßig polygonalen Platten. Letztere waren im Unterkarbon (Mississippium) relativ divers und trugen zu einem ersten moderaten Maximum der Anzahl der Seeigel-Arten zu dieser Zeit bei. Zwei spezialisierte Gruppen des späteren Paläozoikums hatten eine stark erhöhte Anzahl an Ambulakralplatten und -füßchen: die Lepidesthidae (Oberdevon bis Unterperm) mit meist kugel- bis eiförmigem Gehäuse, und die Proterocidaridae (Oberdevon bis Mitteltrias) mit stark abgeflachtem Gehäuse und vergrößerten Füßchen auf der Körper-Unterseite.
Erstmals im Oberdevon tritt die Familie Archaeocidaridae auf, die sich von allen anderen paläozoischen Seeigeln durch die deutlich größeren Stacheln auszeichnet. Von ihr stammen alle modernen Seeigel (Seeigel-Kronengruppe) ab. Die ersten Seeigel mit fest zusammengefügtem Gehäuse und zweireihigen Ambulakral- und Interambulakralreihen sind aus dem Mittelperm bekannt und gehören zur Familie Miocidaridae. Der Großteil der paläozoischen Seeigel-Gruppen verschwand bei dem verheerenden Aussterbe-Ereignis an der Perm-Trias-Grenze, nach aktuellen Erkenntnissen müssen jedoch mindestens drei Linien bis in die Trias überlebt haben. Die mit Abstand artenreichste Seeigel-Fauna der Trias ist aus der mittel- bis obertriassischen St. Kassian-Formation der Dolomiten (Norditalien) bekannt und besteht überwiegend aus isolierten Stacheln und Gehäuse-Fragmenten. Ein Großteil der beschriebenen Arten gehört frühen Linien der Cidaroida (Lanzenseeigel) an, vereinzelt lassen sich auch schon Vertreter der Euechinoidea nachweisen, irreguläre Seeigel fehlen jedoch. Auch aus dem mitteleuropäischen Muschelkalk (Mitteltrias) sowie der Trias von Peru sind einige Seeigel-Arten bekannt. Im anschließenden Jura fand eine große Radiation der Seeigel statt, viele Großgruppen moderner Seeigel lassen sich erstmals im Jura fossil nachweisen. Im frühen Jura gingen zudem die ersten irregulären Seeigel aus regulären Vorfahren hervor, vermutlich als Anpassung an das Leben auf weichem Sediment und zunächst noch ohne vollständig eingegraben zu leben. Wichtige Fundstellen befinden sich v. a.
Sources: de.wikipedia.org
in Europa, etwa in England, Frankreich, Deutschland und der Schweiz. Bedeutende Gruppen jurassischer Seeigel gehören sowohl zu den Cidaroida (z. B. Rhabdocidaridae, Polycidaridae, Cidaridae), den regulären Euechinoidea (z. B. Pedinidae, Hemicidaridae, Acrosaleniidae), als auch zu den Irregularia (z. B. Pygasteridae, Holectypidae, Clypeidae, Nucleolitidae, Collyritidae, Disasteridae). In der Kreidezeit diversifizierten sich insbesondere die irregulären Seeigel weiter und wurden zu einem wichtigen Bestandteil benthischer Ökosysteme. Gattungen wie Conulus und Galerites (beide Ordnung Echinoneoida), Echinocorys (Ordnung Holasteroida) und Micraster (Ordnung Spatangoida) sind in Ablagerungen der Oberkreide häufig zu finden, unter anderem in Feuerstein-Erhaltung an der Küste der Ostsee. Bei den regulären Seeigeln blieben Vertreter der Cidaroida (v. a. Psychocidaridae und Cidaridae) bedeutend, bei den Euechinoidea besonders die heute größtenteils ausgestorbenen Gruppen Phymosomatoida und Salenioida. Wichtige Fundstellen liegen z. B. in England, Frankreich, Deutschland, Nordafrika, auf der Arabischen Halbinsel und in Argentinien. Vom Aussterbe-Ereignis an der Kreide-Paläogen-Grenze waren Seeigel relativ stark betroffen, viele der typischen Kreide-Faunen verschwanden spätestens im Laufe des Paläozäns. Eine starke adaptive Radiation im frühen Paläogen kulminierte schließlich im Eozän und Miozän in der vermutlich größten Diversität unter Seeigeln in der Erdgeschichte, mit einer Unterbrechung im Oligozän.
Sources: de.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
Sealed, protected from light, and refrigerated at two to eight degrees Celsius for most research material. Desiccated storage limits moisture uptake. Allow the vial to reach room temperature before opening to prevent condensation.